Devices/Safety Alert·FDA MedWatch Safety Alerts

Early Alert: Insulin Pump Issue from Insulet

HighPublished Jun 4, 2026· AI-analyzed Jun 4, 2026View original FDA source
AI-generated regulatory interpretation. The four sections below are an analyst-style summary produced by an AI model from the original FDA source. Always verify against the source before any regulatory, clinical, or commercial decision.
What happened

Insulet has identified a defect in certain Omnipod Pods involving a tear in the tubing that can cause insulin to leak outside the device rather than being delivered to the patient.

Who it affects

This affects Insulet, users of the Omnipod system, and professional teams responsible for complaint handling and medical device reporting (MDR).

Why it matters

Failure to deliver insulin as programmed presents a significant clinical risk of hyperglycemia. From a regulatory standpoint, this indicates a mechanical failure in the fluid path, which may necessitate a formal recall, rigorous root cause analysis of the assembly process, and an evaluation of current quality control measures for tubing integrity.

Practical takeaway

QA teams should review manufacturing records for tubing integrity checks, while Regulatory and PV teams must prepare for potential increases in adverse event reporting related to under-delivery of medication. Verification of lot-specific distribution lists for potential field actions is advised.

FDA source material

Certain Omnipod Pods may have a tear in the tubing that allows insulin to leak outside the Pod instead of being delivered to the body. <br>

Open in openFDA / FDA.gov
AI-generated interpretation. Always verify critical decisions against the original FDA source. Generated with google/gemini-3-flash-preview.